Market Place
Sourcing Support
ElectroCore buys NeuroMetrix and its Quell fibromyalgia wearable
20 Dec 2024 //
FIERCE BIOTECH
NeuroMetrix Reports Q3 2024 Business Highlights
05 Nov 2024 //
GLOBENEWSWIRE
NeuroMetrix Reiterates its Review of Strategic Alternatives
13 Aug 2024 //
GLOBENEWSWIRE
NeuroMetrix Reports Q2 2024 Highlights And Strategic Review Update
06 Aug 2024 //
GLOBENEWSWIRE
NeuroMetrix Schedules Q2 2024 Update Call
31 Jul 2024 //
GLOBENEWSWIRE
NeuroMetrix Reports Q1 2024 Business Highlights
15 May 2024 //
GLOBENEWSWIRE
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
19 Apr 2024 //
GLOBENEWSWIRE
NeuroMetrix Announces Publication Demonstrating that DPNCheck Accurately
14 Mar 2024 //
GLOBENEWSWIRE
NeuroMetrix announces patients with fibromyalgia have been prescribed Quell
13 Mar 2024 //
GLOBENEWSWIRE
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
22 Feb 2024 //
GLOBENEWSWIRE
NeuroMetrix Announces Date for Fourth Quarter and Full Year 2023 Conference
15 Feb 2024 //
GLOBENEWSWIRE
NeuroMetrix Announces Review of Strategic Options to Promote Growth
13 Feb 2024 //
GLOBENEWSWIRE
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
08 Jan 2024 //
GLOBENEWSWIRE
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell
12 Dec 2023 //
GLOBENEWSWIRE
NeuroMetrix Announces One-for-Eight Reverse Stock Split
20 Nov 2023 //
GLOBENEWSWIRE
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
30 Oct 2023 //
GLOBENEWSWIRE
NeuroMetrix Reports Q3 2023 Business Highlights
26 Oct 2023 //
GLOBENEWSWIRE
NeuroMetrix Announces Date for Third Quarter 2023 Business Conference
23 Oct 2023 //
GLOBENEWSWIRE
NeuroMetrix and the National Fibromyalgia Association to Collaborate
02 Oct 2023 //
GLOBENEWSWIRE
NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
28 Sep 2023 //
GLOBENEWSWIRE
NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
30 Aug 2023 //
GLOBENEWSWIRE
NeuroMetrix Reports Q2 2023 Business Highlights
27 Jul 2023 //
GLOBENEWSWIRE
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Conference
20 Jul 2023 //
GLOBENEWSWIRE
NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
11 Jul 2023 //
GLOBENEWSWIRE
Recent Publications Demonstrate Utility of DPNCheck® for High-Risk Diabetes
28 Jun 2023 //
GLOBENEWSWIRE
Quell Demonstrates Encouraging Trial Results in Chemotherapy Induced CIPN
31 May 2023 //
GLOBENEWSWIRE
NeuroMetrix Reports Q1 2023 Financial Results
03 May 2023 //
GLOBENEWSWIRE
NeuroMetrix to Exhibit Quell Fibromyalgia and Present New Clinical Data
21 Mar 2023 //
GLOBENEWSWIRE
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
NeuroMetrix Announces Date for Fourth Quarter & Full Year 2022 Financial Results
16 Feb 2023 //
GLOBENEWSWIRE
NeuroMetrix Announces Launch of DPNCheck 2.0, Screening Test
23 Jan 2023 //
GLOBENEWSWIRE
NeuroMetrix to Introduce Quell® Fibromyalgia at the ACR2022
08 Nov 2022 //
GLOBENEWSWIRE
NeuroMetrix plots launch of fibromyalgia treatment device
04 Nov 2022 //
FIERCEBIOTECH
NeuroMetrix Reports Q3 2022 Financial Results
20 Oct 2022 //
GLOBENEWSWIRE
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results
12 Oct 2022 //
GLOBENEWSWIRE
NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales
01 Sep 2022 //
GLOBENEWSWIRE
NeuroMetrix Announces Date for Q2 2022 Financial Results Conference Call
14 Jul 2022 //
GLOBENEWSWIRE
Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization
19 May 2022 //
GLOBENEWSWIRE
NeuroMetrix Announces Date for Q1 2022 Financial Results
19 Apr 2022 //
GLOBENEWSWIRE
NeuroMetrix Reports Quell Wearable Neuromodulator to be Evaluated
24 Feb 2022 //
GLOBENEWSWIRE
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
27 Jan 2022 //
GLOBENEWSWIRE
NeuroMetrix Receives FDA BTD for CIPN with its Wearable Technology
18 Jan 2022 //
GLOBENEWSWIRE
NeuroMetrix Announces Submission of FDA De Novo Request for Treatment
06 Oct 2021 //
GLOBENEWSWIRE
NeuroMetrix Announces Participation in the Center to Stream Healthcare (C2SHIP)
05 Oct 2021 //
GLOBENEWSWIRE
NeuroMetrix Publication Randomized Controlled Wearable Neurostimulation Tech
26 Jul 2021 //
GLOBENEWSWIRE
NeuroMetrix Gets Breakthrough Device Designation for Treatment of Fibromyalgia
20 Jul 2021 //
GLOBENEWSWIRE
NeuroMetrix, Inc. Announces Date for Financial Results Conference Call
15 Jul 2021 //
GLOBE NEWSWIRE
NeuroMetrix Reports that Quell Technology is to be Evaluated for NMOSD
15 Jun 2021 //
GLOBENEWSWIRE
